01—Abstract
Summary
Summary of the 8-K filed April 28, 2026. Cited figures are marked; the original filing is the authoritative source.
HCA Healthcare, Inc. (HCA) filed an 8-K on April 28, 2026, detailing the results of its Annual Meeting of Stockholders held on April 23, 2026.
The meeting saw strong participation, with over 209 million shares represented. A key outcome was the overwhelming election of all nine director nominees to the Board of Directors, indicating robust shareholder confidence in the current leadership and governance structure. Furthermore, the Company's appointment of Ernst & Young LLP as its independent registered public accounting firm for 2026 received broad ratification, underscoring shareholder trust in the auditing process.
Shareholder approval was also given to the advisory resolution on executive compensation, suggesting alignment between management's pay practices and investor sentiment. However, two shareholder proposals, one concerning healthcare consequences reporting and another on shareholders' right to act by written consent, failed to gain majority support.
02—Key points
Key Highlights
- All nine director nominees were overwhelmingly elected to the Board of Directors, reflecting strong shareholder support for HCA's leadership.
- The appointment of Ernst & Young LLP as the independent registered public accounting firm for 2026 was ratified by a significant majority of votes.
- Shareholders approved the non-binding advisory resolution on the company's executive compensation, indicating satisfaction with compensation practices.
- A significant majority of votes were cast against the shareholder proposal requesting a report on healthcare consequences.
- The shareholder proposal advocating for shareholders' right to act by written consent was also not approved by a substantial margin.
- A total of 209,777,472 shares, representing approximately 93.76% of outstanding shares, were represented at the Annual Meeting.
- Broker non-votes were recorded for director elections and executive compensation, but not for the ratification of the independent auditor.
03—Questions
Frequently Asked Questions
What were the main outcomes of HCA Healthcare's 2026 Annual Meeting of Stockholders?
The primary outcomes included the election of all nine director nominees, the ratification of Ernst & Young LLP as the independent auditor for 2026, and the approval of the advisory resolution on executive compensation. Two shareholder proposals, one on healthcare consequences and another on written consent, were not approved.
Did shareholders express confidence in HCA's current board and management?
Yes, the overwhelming election of all nine director nominees suggests a strong vote of confidence from shareholders in the company's current board and its oversight of management.
What was the shareholder sentiment regarding executive compensation?
Shareholders approved the non-binding advisory resolution on executive compensation with a significant majority, indicating that the compensation practices outlined in the proxy statement were generally aligned with investor expectations.
Why did the shareholder proposals regarding healthcare consequences and written consent fail to pass?
These proposals did not receive majority shareholder support. The proposal on healthcare consequences was voted against by a substantial margin, and the proposal on the right to act by written consent also failed to achieve majority approval, indicating that shareholders either disagreed with the proposals' substance or preferred the company's existing policies.
04—Continue